Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | EIF4E | P06730 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30417625 | 0.85 | KDM4E (0.49) | PDPK1CYP2A6CASP6METAP1 | |
| SCHEMBL29228617 | 0.85 | KDM4E (0.49) | PDPK1CYP2A6CASP6METAP1 | |
| SCHEMBL4560363 | 0.80 | MKNK1 (0.50) | EIF4EMKNK1MKNK2IKBKBCHUK | |
| SCHEMBL30417023 | 0.80 | L3MBTL1 (0.50) | CASP6METAP1 | |
| SCHEMBL29228625 | 0.80 | L3MBTL1 (0.50) | CASP6METAP1 | |
| SCHEMBL30416661 | 0.80 | SLC6A9 (0.39) | PDPK1CYP2A6CASP6METAP1 | |
| SCHEMBL30517722 | 0.79 | CSNK1A1 (0.50) | CHEK2PDPK1ADORA2AADORA1 | |
| SCHEMBL995828 | 0.79 | CSNK1A1 (0.50) | CHEK2PDPK1ADORA2AADORA1 | |
| Hydrochloric Acid SCHEMBL30810223 | 0.77 | CSNK1A1 (0.49) | CHEK2PDPK1ADORA2AADORA1 | |
| SCHEMBL30892434 | 0.77 | CYP2A6 (0.42) | EIF4ECYP2A6MKNK1MKNK2IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344003-B2 | 2-pyridinecarboxamide derivatives | MSD K. K. (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20100041660-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | MSD K.K. (JP) | 2010-02-18 | — | — | US | disclosed |
| CN-100378094-C | Novel 2-pyridinecarboxamide derivatives | BANYU PHARMA CO LTD (JP) | 2008-04-02 | — | — | CN | disclosed |
| CN-1747951-A | Novel 2-pyridinecarboxamide derivatives | BANYU PHARMA CO LTD (JP) | 2006-03-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041660-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | GCKR, GCK, HK2 | CHEK2 3062/4885EIF4E 1037/4885PDPK1 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.